Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 5, 2007, Pages 1054-1063

  Jockers Scherübl, Maria C ^a   Wolf, Theresa ^a   Radzei, Nicole ^a   Schlattmann, Peter ^a   Rentzsch, Johannes ^a   Gómez Carrillo de Castro, Ana ^a   Kühl, Klaus Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cannabis; Cognition; Cognitive dysfunction; Residual effects; Schizophrenia

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MALE; MENTAL PATIENT; MENTAL PERFORMANCE; NEUROPSYCHOLOGY; PSYCHOLOGIC TEST; SCHIZOPHRENIA;

ADULT; COGNITION; FEMALE; HUMANS; INTELLIGENCE TESTS; MALE; MARIJUANA ABUSE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34249741613     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.03.006     Document Type: Article

References (68)

1. Ackenheil M., Stotz G., and Dietz-Bauer R. Mini-Internationales Neuropsychiatrisches Interview, MINI Plus (German Version 5.0.0.) (1998)
2. Addington J., and Addington D. Cognitive functioning in first-episode schizophrenia. Rev Psychiatry Neurosci 27 (2002) 188-192
3. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Associated Press, Washington, DC
4. Andreasson S., Allebeck P., and Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand 79 (1989) 505-510
5. Arndt S., Tyrrell G., Flaum M., and Andreasen N.C. Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychol Med 22 (1992) 379-388
6. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184 (2004) 110-117
7. In: Benkert O., and Hippius H. (Eds). Kompendium der Psychiatrischen Pharmakotherapie (2003), Springer, Berlin
8. Carey K.B., Carey M.P., and Simons J.S. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis 191 (2003) 300-308
9. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., Brown G.M., and Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry 52 (1991) 26-30
10. Cornblatt B.A., Risch N.J., Faris G., Friedman D., and Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. findings about sustained attention in normal families. Psychiatry Res 26 (1988) 223-238
11. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 (2004) 765-774
12. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142 (1999) 295-301
13. Fried P., Watkinson B., James D., and Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 166 (2002) 887-891
14. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
15. Harrison E.R., Haaga J., and Richards T. Self-reported drug use data what do they reveal?. Am J Drug Alcohol Abuse 19 (1993) 423-441
16. Heaton R.K., Chelune G.J., and Talley J.L. Wisconsin card sorting test manual - revised and expanded (1993), Psychological Assessment Resources, Odessa, FL
17. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 (1998) 426-445
18. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.-U., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330 (2005) 11-14
19. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.-P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115 (2005) 3104-3116
20. Jockers-Scherübl M.C., Matthies U., Danker-Hopfe H., Lang U.E., Mahlberg R., and Hellweg R. Cannabis raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 17 (2003) 429-435
21. Jockers-Scherübl M.C., Danker-Hopfe H., Mahlberg R., Selig F., Schürer F., Lang U.E., et al. Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371 (2004) 79-83
22. Jockers-Scherübl M.C., Rentzsch J., Danker-Hopfe H., Radzei N., Schürer F., and Bahri S. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neurosci Lett 400 (2006) 262-266
23. Jonkman C.M., Hijman R., v. Dijk D., v. d. Brink W., and Kahn R.S. The effect of cannabis on verbal memory in schizophrenia: preliminary results. Schizophr Res Suppl. 53 (2002) 202
24. Joyal C.C., Hallé P., Lapierre D., and Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 63 (2003) 297-299
25. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuro-Psychopharmacol 28 (2004) 849-863
26. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
27. Keefe R.S., Eesley C.E., and Poe M.P. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57 (2005) 688-691
28. Keefe R.S., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M.M., et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59 (2006) 97-105
29. Kranzler H. Verbal learning and memory deficits in early-onset schizophrenia. Schizophr Res Suppl. 81 (2006) 198
30. Lambe E., Krimer L., and Goldman-Rakic P.S. Differential postnatal development of catecholamine and serotonin inputs to identified neurons in prefrontal cortex of rhesus monkeys. J Neurosci 20 (2000) 8780-8787
31. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B (Multiple-choice vocabulary test of intelligence) (1991), PERIMED-Spitta Medizinische Verlagsgesellschaft mbH, Nürnberg
32. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioural characterization, pharmacological specification, and anatomical localization. Psychopharmacology (Berl) 184 (2006) 523-539
33. Lezak M.D., Howieson D.B., and Loring D.W. Neuropsychological assessment. 4rd edition (2004), Oxford University Press, Oxford
34. Linszen D.H., Dingemans P.M., and Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51 (1994) 273-279
35. Liraud F., and Verdoux H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 28 (2002) 160-168
36. Margolese H.C., Malchy L., Negrete J.C., Tempier R., and Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 67 (2004) 157-166
37. Marenco S., and Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12 (2000) 501-527
38. Mass R., Bardong C., Kindl K., and Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology 34 (2001) 209-214
39. Mueser K.T., Drake R.E., and Wallach M.A. Dual diagnosis: a review of etiological theories. Addict Behav 23 (1998) 717-734
40. National Institut of Mental Health. CGI. Clinical Global Impressions. In: Guy W., and Bonato R.R. (Eds). Manual for the EDCEU assessment battery. 2. rev. ed. (1976), Cevy Chase, Maryland 12-1-12-6
41. Nelson H.E. National Adult Reading Test (NART). 2nd ed (1991), NFER-NELSON, Windsor, England NART-Revised
42. Palmer B.W., Heaton R.K., and Paulsen J.S. Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology 11 (1997) 437-446
43. Pencer A., and Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 28 (2003) 48-54
44. Pope Jr. H.G., Gruber A.J., Hudson J.I., Huestis M.A., and Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58 (2001) 909-915
45. Pope Jr. H.G., Gruber A.J., Hudson, Cohane G., Huestis M.A., and Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 69 (2003) 303-310
46. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epiodemiologic catchment area (ECA) study. JAMA (1990) 2511-2518
47. Reischies F.M., Wertenauer F., and Kühl F.-P. Der "Lector" - ein Untersuchungsverfahren zur Bestimmung des verbalen Bildungsniveaus. Nervenarzt 76 (2005) 849-855
48. Reitan R.M., and Wolfson D. The Halstead-Reitan neuropsychological test battery (1985), Neuropsychological Press, Tucson
49. Salyers M.P., and Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 48 (2001) 109-123
50. Sarne Y., and Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4 (2005) 677-884
51. Schneider M., and Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28 (2003) 1760-1769
52. Sevy S., Robinson D.G., Solloway S., Alvir J.M., Woerner M.G., Bilder R., et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 104 (2001) 367-374
53. Shaw P., Greenstein D., Lerch J., Clasen L., Lenroot R., Gogtay N., et al. Intellectual ability and cortical development in children and adolescents. Nature 440 (2006) 676-679
54. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15 (2005) 319
55. Skosnik P.D., Spatz-Glenn L., and Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 48 (2001) 83-92
56. Smit F., Bolier L., and Cuijpers P. Cannabis and the risk of later schizophrenia: a review. Addiction 99 (2004) 425-430
57. Solowij N., et al., for the Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287 (2002) 1123-1131
58. Stirling J., Lewis S., Hopkins R., and White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 75 (2005) 135-137
59. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol Clin Exp 21 (2006) 245-254
60. Van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156 (2002) 319-327
61. Veen N.D., Selten J.-P., van der Tweel I., Feller W.G., Hoek H.W., and Kahn R.S. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 161 (2004) 501-506
62. Wechsler D. Wechsler adult intelligence scale - revised (1981), The Psychological Corporation, New York
63. Wechsler D. Wechsler memory scale - revised (1987), The Psychological Corporation, San Antonio, AZ
64. Weinberger D.R. Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 45 (1999) 395-402
65. Wilson W., Mathew R., Turkington T., Hawk T., Coleman R.E., and Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 19 (2000) 1-22
66. Wittchen H.-U., Zaudig M., and Fydrich T. Strukturiertes Klinisches Interview für DSM IV, Achse I+ II (1997), Hogrefe, Göttingen
67. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
68. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self-reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325 (2002) 1199